Promoting treatment adherence.
Improving outcomes.
Enhancing patient support.
BEAMER is the latest Innovative Medicines Initiative international consortium to address the emerging challenge of patient adherence to prescribed treatments.
Each year, this health issue contributes to approximately 200,000 premature deaths in the European Union and an estimated €125 billion in avoidable hospitalisations, emergency care and adult outpatient visits—but hope for real change is here.
With the support of the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA), 28 public and private European partners from academia, civil society and industry will embark on a 5-year undertaking to impact physicians and patients’ lives for the better.
Curious to know how BEAMER is guiding the way?
Supported by a grant from IMI, the project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034369. This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation programme, the European Federation of Pharmaceutical Industries and Associations [EFPIA] and Link2Trials. The total budget is 11.9 M€ for a project duration of 60 months.
Disclaimer:
Information on this website reflects project owner’s views and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained therein.